Analysts Anticipate Allakos Inc (NASDAQ:ALLK) to Post ($0.45) EPS

Allakos Inc (NASDAQ:ALLK) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus target price of $96.00 for the company and are forecasting that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also given Allakos an industry rank of 90 out of 256 based on the ratings given to its competitors.

ALLK has been the topic of several recent analyst reports. William Blair restated a “buy” rating on shares of Allakos in a research report on Friday, August 9th. Zacks Investment Research downgraded shares of Allakos from a “buy” rating to a “hold” rating in a research report on Friday, August 16th.

ALLK traded down $2.23 during trading on Thursday, hitting $87.50. The company’s stock had a trading volume of 332,107 shares, compared to its average volume of 477,835. Allakos has a one year low of $29.34 and a one year high of $92.84. The business’s 50 day simple moving average is $52.43 and its 200-day simple moving average is $43.20.

Allakos (NASDAQ:ALLK) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. Equities analysts forecast that Allakos will post -1.83 earnings per share for the current fiscal year.

In other news, Director John P. Mckearn sold 38,732 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $39.80, for a total transaction of $1,541,533.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John P. Mckearn sold 53,906 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $39.57, for a total transaction of $2,133,060.42. The disclosure for this sale can be found here. Insiders have sold a total of 186,373 shares of company stock worth $7,408,059 over the last 90 days. Insiders own 52.11% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in Allakos in the 2nd quarter valued at $63,000. BNP Paribas Arbitrage SA increased its holdings in shares of Allakos by 4,853.8% during the first quarter. BNP Paribas Arbitrage SA now owns 3,220 shares of the company’s stock valued at $130,000 after purchasing an additional 3,155 shares during the period. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Allakos during the first quarter valued at $142,000. SG Americas Securities LLC acquired a new position in shares of Allakos during the first quarter valued at $153,000. Finally, Metropolitan Life Insurance Co NY increased its holdings in shares of Allakos by 66.5% during the first quarter. Metropolitan Life Insurance Co NY now owns 4,931 shares of the company’s stock valued at $199,000 after purchasing an additional 1,970 shares during the period. Hedge funds and other institutional investors own 53.48% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Featured Article: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.